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ABSTRACT
A new method is described for the quantitative detec-
tion of IgE antibodies, based on IgE capture with a
specific antibody, reaction with liquid-biotinylated
allergens and biotinylated anti-IgE and immunoenzy-
matic development of the reaction (reverse enzyme
allergosorbent test). Using a reference system based
on the World Health Organization IgE International
standard, this method determines total IgE in the
range 2–100kU/L and specific IgE in the range 
0.2–100 kU/L, from which the specific/total ratio,
called ‘specific IgE density’, can be calculated. This
procedure has been applied to the study of specific IgE
in 23 sera from patients polysensitized to pollen and
mite allergens: 11 with asthma and 12 with  rhinitis.
The sensitivity and reproducibility of the method were
evaluted. Sera from asthmatic patients showed higher
cumulative levels of specific IgE (mean density 57.7%)
than sera from rhinitic patients (mean density 32.6%).
The clinical significance of specific IgE density in
patients with multiple sensitizations is discussed.
Key words: allergens, IgE density, radioallergo-
sorbent test, reverse enzyme allergosorbent test, 
specific IgE, total IgE.
INTRODUCTION
When atopic individuals are exposed to environmental
antigens, pathologic overproduction of allergen-specific
IgE may arise, causing allergic diseases, such as rhinitis,
conjunctivitis, asthma, atopic dermatitis and anaphylaxis.
The diagnosis of allergic sensitization is based on skin
testing or in vitro detection of allergen-specific IgE in
serum or plasma samples by radioallergosorbent test
(RAST).1,2 This is an allergosorbent test where allergens
are chemically bound to a solid phase. This places some
limits on the quantitative evaluation of results, which
reflect both the quantity and the affinity of IgE anti-
bodies.3 Recently, a new version of the RAST, the CAP
system, has been developed,4,5 using a high-density solid
phase and a reference curve based on the binding of
standard IgE and an anti-IgE antibody bound to the solid
phase, allowing the expression of results in International
Units (kU/L) related to the World Health Organization
(WHO) IgE standard.
A limitation of RAST is the interference due to IgG aller-
gen-specific antibodies, which compete with IgE and
render the test unreliable for monitoring patients in the
course of immunotherapy.6 This limitation is partly over-
come in the CAP version, where the high density of allergen
obtained by means of a polymeric high-surface solid phase
allows the IgG–IgE competition to be minimized.
Some years after the evolution of RAST, Spanish inves-
tigators developed a new method for the detection of
allergen-specific IgE, the reverse enzyme allergosorbent
test (REAST). It is an enzyme immunoassay (EIA) based on
the capture of IgE by a specific anti-human-IgE antibody
fixed to a microplate (IgE-capture microplate) and a sub-
sequent reaction with an allergen conjugated with an
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enzyme.7–9 Alternatively, biotinylated allergens can be
used and subsequently reacted with a streptavidin
enzyme and a chromogenic substrate.10,11 The test results
are read on a reference curve, obtained by incubating
reference sera with known titers of IgE (in relation to the
WHO international standard for IgE) with the same IgE-
capture microplate and reacting with a biotinylated
anti-IgE antibody. The results are then expressed in
International Units (kU/L). Advantages of REAST com-
pared to RAST are: (i) the complete avoidance of
interference by allergen-specific antibodies belonging 
to the IgG isotype, which are common in the course of
specific immunotherapy and against food allergens,
which are completely removed after the IgE capture;10
and (ii) the possibility of making the test completely auto-
mated, due to the presence of a unique solid phase and
liquid (biotinylated) allergens. A preliminary study on sera
from patients with monosensitization and polysensitiza-
tion allowed us to determine the specificity and sensitivity
of REAST compared with RAST and a skin prick test. A
further preliminary study has been performed to compare
REAST and CAP. An important feature of REAST is that the
same IgE-capture microplate can be used to detect aller-
gen-specific IgE and total IgE, with the same in the
reference curve. Starting from this point, we have devel-
oped, and describe in the present article, a particular
version of the REAST procedure directed to the simultane-
ous detection of specific and total IgE, which allows the
calculation of the specific IgE density as a percentage of
total IgE. The calculation of this parameter by conven-
tional methods (e.g. RAST for specific IgE and paper
radioimmunosorbent test (PRIST) or similar assays for
total IgE) is subject to criticism, because IgE may act as
antibodies in RAST and as antigens in assays for total IgE.
The two reactions have different antibody–antigen affini-
ties and time-kinetics (Falagiani and Rapisarda, unpubl.
data, 1995).
The particular version of REAST procedure described in
the present paper, called REAST density, has been applied
to the analysis of 23 sera from polysensitized asthmatic
and rhinitic patients. The value of this test in indicating the
clinical sensitivity to offending allergens, evaluated by
specific provocation tests, is discussed.
METHODS
Sera
Twenty-three sera, from allergic patients sensitized to two
or more allergens, were studied; 12 had rhinitis (eight
with seasonal and four with perennial symptoms) and 11
suffered mainly from asthma (three with seasonal and
eight with perennial symptoms). All the sera were divided
into small aliquots and kept at – 20°C until used.
Reagents for REAST
The REAST reagents were from a commercial source
(Realtest® Density kit; Lofarma SpA, Milan, Italy). The
technical features of the components of the kit are, briefly,
as follows.
1. An anti-IgE-capture solid phase, consisting of
microplates (8-well polystyrene strips, flat bottomed)
coated with a high-density layer of polyclonal (goat) 
anti-IgE antibody according to Ishikawa et al.12 and sub-
mitted to overcoating with bovine serum albumin (BSA) 
as blocking agent.9 The IgE-isotype specificity of the 
antibody had been previously checked by immuno-
electrophoresis with human sera and ELISA reactivity with
IgG, IgA, IgM and IgE myeloma sera.
2. The allergens, Dermatophagoides pteronyssinus
(Der), Parietaria judaica (Par), Poa pratensis (Poa), Betula
verrucosa (Bet), Olea europea (Ole) and the anti-IgE
antibody (polyclonal, from goat) are biotinylated by 
reaction with activated biotin (e -caproylamido-biotin-
N-hydroxy-succinimide ester). Before use, the absence of
non-specific binding is checked with negative control
human sera.
3. Phosphate-buffered saline (PBS), 0.15 mol/L, pH
7.2, containing 0.05% Tween 20, is included for washing
cycles.
4. Streptavidin-peroxidase is included as an enzymatic
label, tetramethyl-benzidine (TMB) as a chromogenic
substrate and 1 mol/L HCl as a stopping solution.
5. A reference curve of human sera is titrated in terms
of total IgE, with reference to the international IgE stan-
dard (WHO IgE IRP 75/502), at the following
concentrations: 0, 0.2, 0.5, 1.0, 5.0, 10, 25, 50 and
100 kU/L.
Reagents for RAST
A commercial radioimmunoassay (RIA) kit was used, con-
sisting of polystyrene beads solid phase, polyclonal
anti-IgE (from goat) labeled with [125iodine] and a grass
pollen-positive reference curve, (Sferikit®-specific IgE;
Lofarma SpA, Milan, Italy). The RAST radioactivity was
measured with a gamma counter (Cobra; Packard
Instrument Company, Meriden, CT, USA).
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The REAST density assay
All the reagents and samples for the assay were at room
temperature.
Standards for IgE (50 m L at 0, 0.2, 0.5, 1.0, 5.0, 10,
25, 50 and 100 kU/L) and the sera under assay, undi-
luted (for specific IgE) and diluted 1:10 (for total IgE),
were dispensed in duplicate into the anti-IgE-capture
microplate and incubated for 60 min at room tempera-
ture. The liquid was aspirated and washed three times
with 0.35 mL washing solution (automatic washer model
812 SW1; SLT Labinstruments, Milan, Italy). Biotinylated
anti-IgE (100 m L) was dispensed into the wells containing
the standard curve and the 1:10 dilution of samples (for
total IgE) and 100 m L biotinylated allergens dispensed
into wells containing undiluted samples (for specific IgE).
These were incubated for 60 min at room temperature
and then the liquid was aspirated and the wells washed
three times. Streptavidin peroxidase (100 m L) was dis-
pensed into all wells except the two blank wells and
incubated for 30 min at room temperature before the
liquid was aspirated from the wells and five washing
cycles were done. Chromogenic substrate (100 m L) was
dispensed into all wells, including the two blanks, and
incubated for 20 min, avoiding exposure to bright light.
Blocking solution (100 m L) was dispensed into all wells in
the same sequence as for the chromogenic substrate, in
order to maintain the same incubation time for all the
wells. Within 60 min, the optical density (OD) was read at
405 and 450 nm, setting the instrument with the blank
(ELISA reader Spectra; SLT, Labinstruments). The dual
wavelength measurement mode was adopted, with
620 nm reference wavelength, to eliminate any influence
caused by the microplate itself (fingerprints, scratches,
dust etc.).
The RAST assay
The routine RAST procedure was followed: (i) incubation
of serum samples with solid phase; (ii) washing cycle; (iii)
incubation with [125I]-anti-IgE; (iv) washing cycle; and (v)
measurement of radioactivity. The results were expressed
in arbitrary RAST units, in a range from 0.35 to 17.5 on
the basis of a four-class reference curve consisting of a
pool of grass-positive sera.
Calculation
The mean OD of duplicates was calculated. The first
part of the reference curve was plotted by inserting 
the OD at 450 nm of the standards 0, 0.5, 1, 5 and
25 kU/L. The 25 kU/L standard was used in each
experiment to calculate the OD 450 nm/OD 405 nm
ratio, used as a correction factor for subsequent stan-
dards. The second part of the reference curve was
constructed by inserting the OD at 405 nm of the 50
and 100 kU/L standards, multiplied by the correction
factor. Therefore, the 25 kU/L standard represents the
link between the two parts of the reference curve. This
unusual procedure was adopted to obtain a broad-
range reference curve from 0.2 to 100 kU/L. The OD
readings obtained with samples diluted 1:10 and
reacted with biotinylated anti-IgE were used to calculate
total IgE. The values were calculated by interpolating
the OD 450 nm readings on the reference curve when it
was smaller than the 25 kU/L standard (corresponding
to 250 kU/L considering the 1:10 dilution), while for
higher values (from 250 to 1000 kU/L) the OD 405 nm
reading was multiplied by the correction factor for 
the interpolation. To calculate specific IgE, the OD
obtained with undiluted sera reacted with biotinylated
allergens were used and the calculation was as above.
Because the serum sample was undiluted, the reading
range was 0.2–100 kU/L of allergen-specific IgE. The
density of specific IgE was calculated according to the
following formula:
(specific IgE kU/L ‚ total IgE kU/L) · 100.
Sensitivity
In the present study, sensitivity is intended as the
minimal detection limit of the assay13 and was evalu-
ated separately for total IgE and specific IgE. For total
IgE, a reference standard was progressively diluted with
phosphate buffer containing 2% bovine serum albumin
and 0.05% NaN3 to give the following IgE concentra-
tions: 0.05, 0.1, 0.25, 0.40 and 0.50 kU/L. For
specific IgE, four allergic sera to Poa, Par, Der and Bet
at known titers of specific IgE (by REAST) were diluted to
obtain the following concentrations of specific IgE:
0.05, 0.1, 0.25, 0.50 and 1.0 kU/L. The diluent alone
was used as a zero point. Eight replicates were run for
each point. Biotinylated anti-IgE was used for total IgE
and the four biotinylated allergens for specific IgE.
The smallest amount of IgE giving an OD (mean – SD)
higher than the OD (mean + SD) of the zero point was
calculated and adopted as a minimal detection limit.
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Reproducibility
The within-run variability was determined by testing, in
the same run, eight replicates of eight positive reference
sera at various IgE levels. The between-run variability was
established by testing the same positive reference sera in
10 different runs. Means, SD and coefficients of variation
(CV) were calculated.
Statistical analysis
The results were analyzed by a simple descriptive statisti-
cal analysis, calculating means, SD, CV% and correlation
coefficient (r).
RESULTS
In a first preliminary evaluation, not described in the
present paper, REAST and CAP have been compared by
assaying 58 allergic sera against the most common aller-
gens. The correlation coefficients obtained were 0.85 for
Der, 0.93 for Poa and 0.85 for Par (Rapisarda and
Cislaghi, unpubl. data, 1998). A second preliminary eval-
uation has been done to compare REAST, RAST (Sferikit®;
Lofarma SpA, Milan, Italy) and skin-prick testing results in
182 patients with a positive clinical history to inhalant
allergens. The sensitivity and specificity of REAST was,
respectively, 90.0 and 94.3% for Der, 96.4 and 96.8% for
Par, 85.9 and 92.3% for Poa and 71.4 and 98.5% for Bet,
while the correlation between REAST and RAST, taking into
account the classes of positivity, was 0.91 for Der, 0.95 for
Par, 0.94 for Poa and 0.76 for Bet.14
Reference curve
The use of double wavelengths has been successful in
obtaining a reference curve with a measuring range from
0.2 to 100 kU/L, as shown in Fig. 1. This measuring
range is comparable to that of the CAP reference curve,
ranging from 0.35 to 100 kU/L. The reproducibility of
the OD of the reference curves in 20 different runs was
calculated on the 25 kU/L linking point and a CV% mea-
surement of 26.6 was obtained.
The procedure to interpolate the part of the curve
exceeding 25 kU/L, multiplying the OD at 405 nm by the
correction factor (OD 450 nm/OD 405 nm), can be
easily automated by a personal computer. In the present
study, an automatic calculation procedure on a personal
computer (using Microsoft Excel) has been developed
and successfully employed.
Minimal detection limit
The minimal detection limit of total IgE, determined with
biotinylated anti-IgE and calculated on the basis of the
mean – SD with respect to the mean + SD of diluent
alone, was 0.1 kU/L and was considered to be the zero
point (Fig. 2a). This sensitivity level means that the test
could also be used for detection of total IgE in cord blood
samples as a predictor for atopic disease, because
0.35 kU/L is the lowest cut-point commonly used.15
The minimal detection limit of specific IgE, determined
with biotinylated allergens, was 0.25 kU/L for Poa and
0.1 kU/L for the other three allergens Par, Der and Bet
(Fig. 2b–e). These sensitivity values are fully consistent
with the clinical use of the test, being the positive thresh-
olds of IgE measurement against different allergens
ranging from 0.40 and 1.00 kU/L, as demonstrated by
receiver operating characteristic (ROC) curve analysis of
CAP results.16
Reproducibility
With regards to reproducibility of the total IgE determina-
tion, the within-run variability with three samples at
different IgE levels gave a CV value of between 4.8 and
10% and the between-run CV was 5.5–9.3% (Table 1).
The reproducibility of specific IgE determination was eval-
uated on three samples. The within-run variability gave
CV values between 1.3 and 2.5% and the between-run
CV values were between 11 and 12% (Table 1).
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Fig. 1 The broad-range reference curve is obtained by com-
bining the optical density (OD) readings at 450 (0.2–25 kU/L)
and 405 nm (25–100 kU/L). The OD (405 nm) values have
been multiplied by the OD (450 nm)/OD (405 nm) correction
factor.
Total and specific IgE determination
The total IgE (T-IgE) values determined by REAST, the
RAST values for specific IgE (S-IgE) and the REAST values
for S-IgE are reported in Tables 2 and 3 for asthmatic and
rhinitic patients, respectively. In the same tables, the
density of S-IgE and their sums are calculated. For total
IgE, the values were, as expected, spread over a wide
range: from 28 to 2060 kU/L for asthmatic (mean 551,
SD 603.4 kU/L) and from 22 to 1130 kU/L for rhinitic
patients (mean 237.9, SD 330.4 kU/L). A comparison
between RAST and REAST results cannot be done for 
S-IgE, because the RAST units are arbitrary and not
related to the kU/L adopted for REAST. Preliminary exper-
iments to determine the equivalence between the two
systems showed that 1 RAST unit on the Sferikit reference
curve corresponds to 4.65 kU/L (Rapisarda, unpubl.
data, 1997). The S-IgE values detected by REAST were
remarkably higher in asthmatic than in rhinitic patients
(means 58.3 and 12.9, respectively). The values of
density of S-IgE, expressed as a percentage ratio of total
IgE, showed a great variability among patients, with a
tendency to be higher in asthmatic than in rhinitic patients
(means 14.1 and 8.0%, respectively). As expected, the
sum of densities showed the same tendency, with means
of 57.7 and 32.6%, respectively.
DISCUSSION
The REAST is a reliable procedure for detecting allergen-
specific IgE antibodies.7–11 Inhibition studies have
demonstrated the efficiency of liquid biotinylated aller-
gens in the binding of IgE antibodies and sensitivity is
good compared with the conventional solid-phase
RAST.17 The new version of the REAST procedure
described in the present paper provides an advantage
over RAST in allowing the determination of the density 
of IgE antibodies, a new parameter corresponding to 
the ratio of specific to total IgE levels. This cannot be
determined with conventional procedures, such as a
combination of RAST for specific IgE and sandwich assay
(PRIST or similar) for total IgE. These differ widely in terms
of the affinity and kinetics of antigen–antibody reactions,
the IgE being an antibody in RAST (binding the allergen
on the solid phase) and an antigen in PRIST-like assays
(bound by anti-IgE antibody on the solid phase). The
grade of IgE-mediated allergic reaction and the severity
of clinical symptoms should be more closely 
correlated to the percentage of IgE antibodies than to
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Fig. 2 Identification of the minimal detection limit of (a) total
IgE and specific IgE to (b) Poa pratensis, (c) Parietaria judaica,
(d) Dermatophagoides pteronyssinus and (e) Betula verrucosa.
Table 1 Reproducibility of the reverse enzyme allergosorbent test
Poa, Poa pratensis; Der, Dermatophagoides pteronyssinus; CV, coefficient of variation.
Within-run variability Between-run variability
No. replicates Mean (kU/L) SD (kU/L) CV (%) Mean (kU/L) SD (kU/L) CV (%)
Total IgE
Sample 1 10 25 1.21 4.8 15.7 1.39 8.9
Sample 2 10 57 5.92 10.4 33.3 5.18 5.5
Sample 3 10 82 8.34 10.2 82.8 7.74 9.3
Specific IgE
Poa+ sample 8 9.4 0.12 1.3 3.13 0.37 11.8
Der+ sample 8 3.58 0.09 2.5 5.63 0.63 11.2
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Table 2 Test results with 11 sera from asthmatic patients
Der, Dermatophagoides pteronyssinus; Par, Parietaria judaica; Poa, Poa pratensis; Bet, Betula verrucosa; Ole, Olea europea; REAST, reverse
enzyme allergosorbent test; RAST, radioallergosorbent test; T-IgE, total immunoglobulin E; S-IgE, specific immunoglobulin E; S-IgE density, S-IgE as
a percentage of T-IgE by REAST.
Patient No. REAST T-IgE Allergens RAST S-IgE REAST S-IgE S-IgE density S-IgE densities (sum)
1 66 Der 0.0 0.0 0.0 98.3
Par 10.6 12.5 18.9
Poa 13.2 30.0 45.4
Bet 2.6 22.5 34.0
2 342 Der 9.0 60.5 17.6 51.7
Par 0.0 0.0 0.0
Poa 28.1 98.3 28.7
Bet 0.9 7.5 2.2
Ole 1.5 9.0 2.6
3 168 Grass 0.6 3.0 1.8 62.1
Ole 1.3 1.5 0.9
Par 24.8 92.5 56.5
Bet 1.3 4.7 2.9
4 670 Der 18.4 253.7 37.8 66.0
Par 25.1 80.0 11.9
Poa 23.2 35.0 14.1
Bet 2.1 15.0 2.2
5 267 Der 5.7 84.0 31.4 70.0
Par 26.4 85.0 31.8
Poa 0.9 0.9 0.3
Ole 0.0 17.5 6.5
6 220 Der 2.8 19.0 8.6 45.6
Par 24.8 60.8 27.5
Poa 10.5 20.0 9.0
Bet 0.7 1.3 0.5
7 385 Der 0.5 3.5 0.9 43.5
Par 2.6 40.0 10.3
Poa 4.2 3.3 0.8
Bet 9.2 121.5 31.5
8 1200 Der 11.1 114.0 9.5 33.9
Par 25.0 292.5 24.3
Poa 0.0 0.0 0.0
Bet 0.0 1.0 0.0
9 28 Der 0.0 13.0 47.1 86.5
Par 3.2 7.3 26.4
Poa 1.3 3.6 13.0
Bet 0.0 0.0 0.0
10 660 Der 0.5 0.7 0.1 41.6
Par 19.7 271.0 41.0
Poa 12.1 0.8 0.1
Bet 2.3 2.7 0.4
11 2060 Der 17.1 670.0 32.5 35.60
Par 11.8 3.9 0.2
Bet 7.7 14.8 0.7
Ole 7.7 45.5 2.2
Mean 551 8.2 58.3 14.1 57.7
SD 603.4 9.1 116.9 16.0 21.0
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Table 3 Test results with 12 sera from rhinitic patients
Der, Dermatophagoides pteronyssinus; Par, Parietaria judaica; Poa, Poa pratensis; Bet, Betula verrucosa; Ole, Olea europea; REAST, reverse
enzyme allergosorbent test; RAST, radioallergosorbent test; T-IgE, total immunoglobulin E; S-IgE, specific immunoglobulin E; S-IgE density, S-IgE as
a percentage of T-IgE by REAST; ND, not determined.
Patient No. REAST T-IgE Allergens RAST S-IgE REAST S-IgE S-IgE density S-IgE densities (sum)
12 108 Der ND 5.7 5.3 32.1
Par ND 15.0 13.8
Poa ND 13.0 12.0
Bet ND 1.1 1.0
13 42 Der ND 0.0 0.0 38.8
Par ND 8.3 19.8
Poa ND 6.2 14.8
Bet ND 1.8 4.3
14 103 Der 0.0 0.4 0.4 15.3
Par 7.3 12.0 11.7
Poa 2.2 1.9 1.9
Bet 0.3 1.5 1.4
15 114 Der 4.0 12.2 10.7 22.7
Par 11.1 10.0 8.8
Poa 1.6 3.7 3.3
Bet 0.0 0.0 0.0
16 544 Par 22.2 145.6 26.8 33.3
Poa 3.2 0.0 0.0
Bet 7.5 20.6 3.8
Ole 2.1 15.1 2.8
17 22 Der 0.0 0.0 0.0 28.0
Par 3.2 5.4 24.7
Poa 0.2 0.7 3.3
Bet 0.0 0.0 0.0
18 47 Der 0.0 0.0 0.0 32.3
Par 4.5 14.6 31.1
Poa 0.4 0.6 1.3
Bet 0.0 0.0 0.0
19 1130 Der 2.5 18.0 1.6 11.0
Par 22.4 100.0 8.9
Poa 5.2 5.5 0.5
Bet 0.0 0.6 0.0
20 73 Der 0.2 0.0 0.0 39.8
Par 10.4 12.0 16.3
Poa 8.0 15.0 20.4
Bet 0.3 1.1 1.4
Ole 0.0 1.2 1.6
21 72 Par 3.1 1.9 2.6 88.0
Poa 19.3 60.0 82.8
Bet 1.0 1.1 1.5
Ole 0.0 0.8 1.1
22 104 Der 0.0 0.0 0.0 32.7
Par 14.2 15.0 14.4
Poa 1.9 10.9 10.5
Bet 1.3 8.1 7.8
23 496 Par 19.8 72.4 14.6 17.7
Poa 11.8 12.2 2.5
Bet 0.4 0.0 0.0
Ole 1.3 3.1 0.6
Mean 237.9 4.7 12.9 8.0 32.6
SD 330.4 6.6 27.0 13.5 19.7
their absolute amount in serum. Immunoglobulin E binds
through the Ce 3 domain to mast cells and basophils 
carrying the high-affinity receptor Fce RI and the reaction
with multivalent antigens elicits the allergic reaction by
triggering intracellular events leading to the activation of
these cells and the release of mediators. The affinity of
IgE for the receptor Fce RI is so high (Kd of approximately
10–10 mol/L) according to Metzger et al.18 that we can
consider circulating antibodies to be the result of over-
production with respect to the whole receptor capacity of
these cells, which concentrate IgE on their surface.
Therefore, it is reasonable to postulate that the
releasability of IgE-bearing cells should be correlated
more to the density of allergen-specific IgE antibodies on
their surface than to the absolute amount of such anti-
bodies in peripheral blood. From this angle, the S-IgE
density seems to be a promising indicator of the clinical
relevance of a given allergen. The clinical relevance of
the new parameter S-IgE density was assessed in a clini-
cal study, where organ sensitivity was studied with nasal
and bronchial specific challenges, and proved to be pos-
itively correlated to S-IgE density (Crimi et al., unpubl.
obs., 1997). In fact, rhinitic patients have shown that spe-
cific IgE density is significantly correlated with nasal
challenge scores (r = 0.72, P < 0.0001), while the
levels of specific IgE expressed as absolute values (kU/L)
are correlated to nasal challenge scores to a lesser extent
(r = 0.48, P < 0.005). In asthmatic patients, the level of
specific IgE was significantly correlated with the maximum
late forced expiratory volume in 1 s (FEV1) decrease only
when it was expressed as specific IgE density (r = 0.53, P
< 0.005) and not when it was expressed as an absolute
value (r = 0.25, P = 0.16). These authors have con-
cluded that, in the majority of patients with multiple
sensitizations, the S-IgE density determined by REAST
appears to be in satisfactory agreement with the
responses to the inhaled allergens.
In terms of the technical aspects of the test, the stan-
dard curve (r = 0.90), the sensitivity (0.1 kU/L) and the
reproducibility, both within-run (CV% 1.3–10) and
between-run (CV% 5.5–12), were considered satisfac-
tory. The T-IgE values determined by REAST have been
compared with the values obtained by PRIST, with
r = 0.987 (Feligioni, unpubl. data, 1997). The biotiny-
lation procedure of allergens was highly reproducible
and could be easily extended to all allergens of clinical
interest. In our laboratory at Lofarma SpA, the REAST
procedure has now been developed for 270 allergenic
sources from pollens, mites, moulds, animal epithelia,
insect venoms, latex and, after conjugation to a protein
carrier (human serum albumin), some antibiotics.
The difference between quantitative REAST (S-IgE) and
density is explained by the mode of calculation. In the
density procedure, the T-IgE value goes into the calcula-
tion and IgE antibodies are expressed as a percentage.
As a consequence, different samples having the same
absolute value of IgE antibodies can give a wide range
of IgE densities. The sum of S-IgE density values in the
patient’s serum always gives a figure below 100%, the
highest value observed being 98.3% (patient 1, asth-
matic group). This limit was observed in the present study
because the allergens tested did not cross-react,
whereas in further studies in progress with cross-reacting
allergens (e.g. hazel, birch, alder) the sum of S-IgE den-
sities often widely exceeds 100%. This is due to the fact
that, because of cross-reactions, the same IgE antibod-
ies recognize several allergenic sources. In the case of
strictly cross-reacting allergens (e.g. D. pteronyssinus
and D. farinae, grass pollens), the use of mixtures pre-
pared by pooling the biotinylated allergens is suggested.
In conclusion, IgE density is proposed as a new
method to evaluate the content of allergen-specific IgE
antibodies in serum samples, based on the simultaneous
detection of total and specific IgE by REAST. This new
procedure promises to offer consistent advantages for
better evaluation of the clinical role of different aller-
gens, particularly in patients with multiple sensitizations.
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